Literature DB >> 31807948

Proton Pump Inhibitors in the Elderly, Balancing Risk and Benefit: an Age-Old Problem.

Takeshi Kanno1, Paul Moayyedi2.   

Abstract

PURPOSE OF REVIEW: Proton pump inhibitors (PPIs) are one of the most prescribed drugs in the developed world and elderly patients are particularly likely to be prescribed acid suppression. There have been reports of many diseases being associated with PPI therapy and the elderly would be particular at risk of any harms these drugs may cause. This review therefore reviews the evidence of the risks and benefits of these drugs. RECENT
FINDINGS: PPIs are very effective at treating acid-related disorders. Recent randomized trials have suggested that the associations between PPI and various diseases are likely to be related to bias and residual confounding and these drugs appear to be safe apart from a possible increase risk of enteric infections. PPIs should be used at the lowest dose and for the shortest duration possible. They are still relatively safe drugs but should only be prescribed for proven indications.

Entities:  

Keywords:  Adverse events; Dementia; Fracture; Mortality; Pneumonia; Proton pump inhibitors

Mesh:

Substances:

Year:  2019        PMID: 31807948     DOI: 10.1007/s11894-019-0732-3

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  75 in total

Review 1.  Gastro-oesophageal reflux disease.

Authors:  Paul Moayyedi; Nicholas J Talley
Journal:  Lancet       Date:  2006-06-24       Impact factor: 79.321

2.  Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose.

Authors:  B Oosterhuis; J H Jonkman; T Andersson; P B Zuiderwijk; J N Jedema
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

3.  Clinical outcomes of laryngopharyngeal reflux treatment: A systematic review and meta-analysis.

Authors:  Jerome R Lechien; Sven Saussez; Antonio Schindler; Petros D Karkos; Abdul Latif Hamdan; Bernard Harmegnies; Lisa G De Marrez; Camille Finck; Fabrice Journe; Marianne Paesmans; Michael F Vaezi
Journal:  Laryngoscope       Date:  2018-12-30       Impact factor: 3.325

4.  Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.

Authors:  Paul Moayyedi; John W Eikelboom; Jackie Bosch; Stuart J Connolly; Leanne Dyal; Olga Shestakovska; Darryl Leong; Sonia S Anand; Stefan Störk; Kelley R H Branch; Deepak L Bhatt; Peter B Verhamme; Martin O'Donnell; Aldo P Maggioni; Eva M Lonn; Leopoldo S Piegas; Georg Ertl; Matyas Keltai; Nancy Cook Bruns; Eva Muehlhofer; Gilles R Dagenais; Jae-Hyung Kim; Masatsugu Hori; P Gabriel Steg; Robert G Hart; Rafael Diaz; Marco Alings; Petr Widimsky; Alvaro Avezum; Jeffrey Probstfield; Jun Zhu; Yan Liang; Patricio Lopez-Jaramillo; Ajay K Kakkar; Alexander N Parkhomenko; Lars Ryden; Nana Pogosova; Antonio L Dans; Fernando Lanas; Patrick J Commerford; Christian Torp-Pedersen; Tomek J Guzik; Dragos Vinereanu; Andrew M Tonkin; Basil S Lewis; Camilo Felix; Khalid Yusoff; Kaj P Metsarinne; Keith A A Fox; Salim Yusuf
Journal:  Gastroenterology       Date:  2019-05-29       Impact factor: 22.682

5.  Uses of proton pump inhibitors and hypomagnesemia.

Authors:  Jen-Tzer Gau; Yu-Xiao Yang; Roger Chen; Tzu-Cheg Kao
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-02-15       Impact factor: 2.890

6.  Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Paul Moayyedi; John W Eikelboom; Jackie Bosch; Stuart J Connolly; Leanne Dyal; Olga Shestakovska; Darryl Leong; Sonia S Anand; Stefan Störk; Kelly R H Branch; Deepak L Bhatt; Peter B Verhamme; Martin O'Donnell; Aldo P Maggioni; Eva M Lonn; Leopoldo S Piegas; Georg Ertl; Matyas Keltai; Nancy Cook Bruns; Eva Muehlhofer; Gilles R Dagenais; Jae-Hyung Kim; Masatsugu Hori; P Gabriel Steg; Robert G Hart; Rafael Diaz; Marco Alings; Petr Widimsky; Alvaro Avezum; Jeffrey Probstfield; Jun Zhu; Yan Liang; Patricio Lopez-Jaramillo; Ajay Kakkar; Alexander N Parkhomenko; Lars Ryden; Nana Pogosova; Antonio Dans; Fernando Lanas; Patrick J Commerford; Christian Torp-Pedersen; Tomek Guzik; Dragos Vinereanu; Andrew M Tonkin; Basil S Lewis; Camilo Felix; Khalid Yusoff; Kaj Metsarinne; Keith A A Fox; Salim Yusuf
Journal:  Gastroenterology       Date:  2019-05-02       Impact factor: 22.682

Review 7.  Prevention of NSAID-induced gastroduodenal ulcers.

Authors:  A Rostom; C Dube; G Wells; P Tugwell; V Welch; E Jolicoeur; J McGowan
Journal:  Cochrane Database Syst Rev       Date:  2002

8.  Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study.

Authors:  Mette Charlot; Erik L Grove; Peter Riis Hansen; Jonas B Olesen; Ole Ahlehoff; Christian Selmer; Jesper Lindhardsen; Jan Kyst Madsen; Lars Køber; Christian Torp-Pedersen; Gunnar H Gislason
Journal:  BMJ       Date:  2011-05-11

9.  Lifestyle factors among proton pump inhibitor users and nonusers: a cross-sectional study in a population-based setting.

Authors:  Frederik Hvid-Jensen; Rikke B Nielsen; Lars Pedersen; Peter Funch-Jensen; Asbjørn Mohr Drewes; Finn B Larsen; Reimar W Thomsen
Journal:  Clin Epidemiol       Date:  2013-12-04       Impact factor: 4.790

10.  Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial.

Authors:  Janusz A Z Jankowski; John de Caestecker; Sharon B Love; Gavin Reilly; Peter Watson; Scott Sanders; Yeng Ang; Danielle Morris; Pradeep Bhandari; Claire Brooks; Stephen Attwood; Rebecca Harrison; Hugh Barr; Paul Moayyedi
Journal:  Lancet       Date:  2018-07-26       Impact factor: 202.731

View more
  5 in total

1.  Drug Prescription Profiles in Patients with Polypharmacy in Spain: A Large-Scale Pharmacoepidemiologic Study Using Real-World Data.

Authors:  Miguel Ángel Hernández-Rodríguez; Ermengol Sempere-Verdú; Caterina Vicens-Caldentey; Francisca González-Rubio; Félix Miguel-García; Vicente Palop-Larrea; Ramón Orueta-Sánchez; Óscar Esteban-Jiménez; Mara Sempere-Manuel; María Pilar Arroyo-Aniés; Buenaventura Fernández-San José; José Ignacio de Juan-Roldán; Ignatios Ioakeim-Skoufa
Journal:  Int J Environ Res Public Health       Date:  2021-04-29       Impact factor: 3.390

2.  Proton Pump Inhibitors Increase the Risk of Autoimmune Diseases: A Nationwide Cohort Study.

Authors:  Sheng-Hong Lin; Yu-Sheng Chang; Tzu-Min Lin; Li-Fang Hu; Tsung-Yun Hou; Hui-Ching Hsu; Yu-Chuan Shen; Pei-I Kuo; Wei-Sheng Chen; Yi-Chun Lin; Jin-Hua Chen; Chi-Ching Chang
Journal:  Front Immunol       Date:  2021-09-30       Impact factor: 7.561

3.  Prescribing trends of proton pump inhibitors, antipsychotics and benzodiazepines of medicare part d providers.

Authors:  Jennifer M Toth; Saumil Jadhav; Holly M Holmes; Manvi Sharma
Journal:  BMC Geriatr       Date:  2022-04-09       Impact factor: 4.070

4.  Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy.

Authors:  Dario Cattaneo; Luca Pasina; Aldo Pietro Maggioni; Andrea Giacomelli; Letizia Oreni; Alice Covizzi; Lucia Bradanini; Marco Schiuma; Spinello Antinori; Annalisa Ridolfo; Cristina Gervasoni
Journal:  Drugs Aging       Date:  2020-11-05       Impact factor: 3.923

5.  The inappropriate use of proton pump inhibitors and its associated factors among community-dwelling older adults.

Authors:  Mohammad Rababa; Abeer Rababa'h
Journal:  Heliyon       Date:  2021-07-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.